Imiglucerase (Cerezyme)

Cerezyme (imiglucerase) is covered only for FDA‑approved Type 1 Gaucher disease and all off‑label uses are excluded. Approval (up to 1 year) requires documentation of deficient β‑glucocerebrosidase activity in leukocytes/fibroblasts or molecular genetic testing confirming a glucocerebrosidase gene mutation, prescription/consultation by a geneticist, endocrinologist, metabolic disorder or lysosomal storage disorder specialist, and dosing limited to 60 U/kg IV no more frequently than every 2 weeks.

"Treatment of individuals with Type 1 Gaucher disease (FDA‑approved indication)."

Sign up to see full coverage criteria, indications, and limitations.